What Is Anticardiolipin and Why Is It Tested?

Anticardiolipin antibodies are immune proteins your body produces against cardiolipin, a fat molecule found in cell membranes. Doctors test for them primarily to help diagnose antiphospholipid syndrome, a condition that raises the risk of abnormal blood clots and pregnancy complications. The test is straightforward, but interpreting a positive result is not, because these antibodies can show up transiently during infections, persist harmlessly for years, or signal a serious clotting disorder depending on the clinical context.

What Cardiolipin Actually Is

Cardiolipin is a phospholipid, a type of fat molecule, that sits almost exclusively in the inner membrane of your mitochondria, the energy-producing structures inside cells. It plays a hands-on role in keeping the machinery of energy production running efficiently, supporting the protein complexes that generate ATP and helping maintain the shape and stability of mitochondrial membranes.¹ The name “cardiolipin” comes from the fact that it was originally isolated from beef heart tissue, which is rich in mitochondria. In a healthy person, the immune system ignores cardiolipin entirely. When antibodies against it appear in your blood, something has gone wrong with immune tolerance.

How the Antibodies Form and What They Really Target

The story of anticardiolipin antibodies is a little more complicated than “antibody meets fat molecule.” In autoimmune disease, these antibodies don’t bind cardiolipin directly. They need a helper protein called beta-2 glycoprotein I (β2-GPI), a plasma protein that normally circulates in your blood and sticks to phospholipid surfaces. β2-GPI acts as a cofactor: it latches onto cardiolipin first, and then the antibody binds the β2-GPI-cardiolipin complex.² This distinction matters because autoimmune anticardiolipin antibodies, the ones linked to clotting and pregnancy loss, are β2-GPI-dependent. Antibodies triggered by infections, on the other hand, can bind cardiolipin without β2-GPI and tend to be clinically harmless.³

This cofactor dependence is why lupus researchers in the early 1990s began studying anti-β2-GPI antibodies separately from anticardiolipin antibodies. Both are now part of the standard antiphospholipid antibody panel, but they capture overlapping yet not identical populations of patients.⁴

How These Antibodies Promote Clotting

Once anticardiolipin antibodies are circulating in sufficient quantities, they tilt your blood’s balance toward clotting through several routes at once. They interfere with natural anticoagulant pathways that normally keep clot formation in check. They activate the cells lining blood vessel walls and the platelets that form clots. And they can trigger complement activation, part of the immune system’s inflammatory cascade, which further damages blood vessels.⁵ The result is an increased tendency to form clots in both arteries and veins, which is why antiphospholipid syndrome can cause such varied problems: deep vein thrombosis, pulmonary embolism, stroke, and heart attack can all stem from the same underlying antibody-driven process.

When Doctors Order the Test

The anticardiolipin test is not part of routine blood work. It gets ordered when a clinical picture raises suspicion for antiphospholipid syndrome. The most common triggers include:

• Unexplained blood clots: Especially in someone younger than expected or without the usual risk factors like immobility, surgery, or cancer.
• Recurrent pregnancy loss: Particularly two or more losses before the tenth week or any loss after the tenth week without another clear explanation.
• Stroke in a young adult: In one case-control study of ischemic stroke patients under 45, anticardiolipin antibodies were present in about one in ten patients, compared with roughly one in a hundred healthy controls.⁶
• Lupus diagnosis: Because antiphospholipid antibodies are common in lupus patients and change the treatment approach.
• Unexplained low platelet count: Thrombocytopenia can be a feature of antiphospholipid syndrome.

The test is also ordered as part of the workup when someone has a false-positive syphilis screening test, since the older syphilis tests use cardiolipin as a reagent and can cross-react with anticardiolipin antibodies.

How the Test Works and What Results Mean

Anticardiolipin antibodies are measured using an ELISA (enzyme-linked immunosorbent assay), a plate-based lab test that detects and quantifies specific antibodies in a blood sample. The test separately measures IgG and IgM isotypes of anticardiolipin antibodies, reported in GPL units and MPL units respectively.⁷ Higher titers generally carry more clinical weight, but the test has a well-known standardization problem: results can vary between laboratories and assay kits because different manufacturers use different calibrators and cutoff values.⁸

A single positive anticardiolipin test does not mean you have antiphospholipid syndrome. To meet the current diagnostic criteria, the antibodies must persist: a second test at least twelve weeks after the first needs to confirm that they are still present. This persistence requirement exists specifically to weed out the transient antibodies that infections produce. The full diagnostic criteria also require at least one clinical event, either a confirmed blood clot or a qualifying pregnancy complication, on top of the persistent lab findings.⁹

Doctors typically order the anticardiolipin test alongside two other tests: lupus anticoagulant and anti-β2-GPI antibodies. Together these make up the antiphospholipid antibody panel. Being positive on all three, called “triple positivity,” is associated with a substantially higher clotting risk than being positive on just one.

Why Low Titers Still Matter in Pregnancy

There has been a longstanding assumption that only moderate-to-high levels of anticardiolipin antibodies are clinically relevant. Recent research challenges this, at least in the context of recurrent miscarriage. A study comparing women with low-titer and medium-to-high-titer antiphospholipid antibodies found that the low-titer group still experienced significant pregnancy complications, underscoring the importance of timely treatment even when antibody levels are modest.¹⁰ The pathology in pregnancy may not be purely about blood clots in the placenta. Evidence suggests that antiphospholipid antibodies can also directly disrupt trophoblast cells, the cells that form the placenta, and trigger inflammation at the interface between mother and fetus.

Transient Positives from Infections and Medications

One of the trickiest aspects of the anticardiolipin test is that infections can trigger temporary production of these antibodies. Syphilis is the most historically famous example, but hepatitis, varicella, measles, and viral pneumonia can all produce transient positive results.¹¹ In most people, infection-triggered anticardiolipin antibodies fade within two to three months and do not cause clotting problems.¹² This is one reason the twelve-week retesting rule exists.

Certain medications can also induce antiphospholipid antibodies. An analysis of global adverse-event reports identified fourteen drugs with a signal for drug-induced antiphospholipid syndrome, including some hormonal contraceptives, the antibiotic minocycline, the anti-inflammatory rofecoxib, the biologic etanercept, interferon beta-1a, the blood pressure drug hydralazine, and several vaccines.

The Syphilis Connection

The history of anticardiolipin testing is tangled up with syphilis screening. In the early 1900s, researchers developed blood tests for syphilis that used cardiolipin extracted from beef heart as the test antigen. The Wassermann reaction, introduced in 1906, was based on this principle: syphilis infection triggers antibodies that react with cardiolipin.¹³ Modern syphilis screening tests like the RPR and VDRL still use cardiolipin-based reagents. When someone tests positive on these screening tests but negative on a confirmatory treponemal test that detects syphilis-specific antibodies, the result is called a biological false positive.¹⁴ These false positives are sometimes the first clue that a patient has circulating antiphospholipid antibodies, and they frequently prompt the dedicated anticardiolipin test.

Anticardiolipin Antibodies in Lupus

People with systemic lupus erythematosus (SLE) are tested for anticardiolipin antibodies almost as a matter of course. In one large study, anticardiolipin antibodies were found in about 42% of lupus patients, compared with roughly 8% of controls. Among the lupus patients, the antibodies were significantly associated with blood clots, fetal loss, and low platelet counts.¹⁵ Knowing a lupus patient’s anticardiolipin status changes clinical decisions: it affects whether blood thinners are recommended, how aggressively other risk factors are managed, and how a pregnancy is monitored.

More recent data from a large Chinese lupus cohort showed that lupus patients who had low platelets and were also positive for antiphospholipid antibodies had lower platelet counts at baseline, more severe disease, and higher relapse rates than those without the antibodies.¹⁶ The more types of antiphospholipid antibodies a patient carries, the worse the platelet trajectory tends to be.

Treatment After a Positive Test and a Clot

If you test persistently positive for anticardiolipin antibodies and have had a blood clot, the standard treatment is long-term anticoagulation, typically with warfarin (a vitamin K antagonist). This is one area where newer blood thinners have not proven to be a good substitute. A meta-analysis of randomized trials found that patients with antiphospholipid syndrome who were put on direct oral anticoagulants (DOACs) instead of warfarin had a higher risk of arterial blood clots, with no clear advantage in bleeding or venous clot prevention.¹⁷

Real-world data from patients positive specifically for anticardiolipin antibodies echoed this concern. While most outcomes between DOACs and warfarin were statistically similar, DOACs were associated with a roughly two-and-a-half-fold higher risk of heart attack.¹⁸ For this reason, most guidelines steer antiphospholipid syndrome patients toward warfarin despite its inconvenience of regular blood monitoring and dietary restrictions.

Pregnancy Management

For women with antiphospholipid antibodies and a history of recurrent pregnancy loss, the combination of low-dose aspirin and heparin (usually a low-molecular-weight form like enoxaparin) is the standard of care. A Cochrane review found that heparin plus aspirin may increase live births by about 27% and roughly halve the risk of pregnancy loss compared with no treatment or other interventions, though the certainty of the evidence was rated low.¹⁹ In one earlier trial that compared the two drugs head to head, the live birth rate was 80% with heparin plus aspirin versus 44% with aspirin alone.²⁰ A smaller study using enoxaparin and low-dose aspirin reported an 86% live birth rate.²¹

Even with treatment, severe late-pregnancy complications like preeclampsia and preterm labor remain a concern. The antibodies appear to damage the placenta through inflammation and direct disruption of placental cell function, not solely through clotting, which may explain why anticoagulation alone does not eliminate all risk.

What If You Test Positive but Have No Symptoms

A persistent positive anticardiolipin result in someone who has never had a clot or pregnancy complication puts you in the category of an “asymptomatic carrier.” This is a surprisingly common situation, and the management is far from settled. A randomized trial of low-dose aspirin versus placebo in persistently positive, asymptomatic individuals found no benefit from aspirin. The overall annual rate of blood clots in these people was low, and when clots did occur, additional risk factors like immobility or oral contraceptive use were usually present.²²

That said, risk is not uniform among carriers. Expert opinion favors considering preventive blood thinners for asymptomatic carriers who also have lupus, who test positive on multiple antiphospholipid tests (especially triple positivity), or who have additional cardiovascular risk factors like smoking or high blood pressure.²³ For low-risk carriers, managing conventional clotting risk factors, staying mobile during long travel, and avoiding estrogen-containing contraceptives are practical steps that likely matter more than any medication.

Children with Antiphospholipid Antibodies

Antiphospholipid syndrome in children is uncommon but tends to be more aggressive than in adults. Children are more likely to present with severe, recurrent clotting events and have a higher chance of developing catastrophic antiphospholipid syndrome, a rare and life-threatening form in which clots form in multiple organ systems simultaneously.²⁴ Nonthrombotic features, such as low platelet counts, livedo reticularis (a mottled skin pattern), and heart valve abnormalities, are also more common in children and may appear before any clotting event. Because the adult diagnostic criteria were not designed with pediatric patients in mind, there are ongoing calls to revise them.²⁵ Pediatric antiphospholipid syndrome can also serve as an early signal that a child may develop lupus or another autoimmune disease later in life.

Effects on the Brain Beyond Stroke

Most discussions of anticardiolipin antibodies focus on clotting, but emerging evidence suggests subtler neurological effects. In a study of community-dwelling older adults who had never had a stroke, those who tested positive for anticardiolipin antibodies performed worse on a standard cognitive screening test. The association was specific to the IgG subtype and appeared to be dose-dependent: higher antibody levels correlated with lower scores.²⁶ The mechanism is not fully understood. It may involve subtle damage to small blood vessels in the brain or direct effects of the antibodies on neural tissue. Whatever the pathway, the finding suggests that anticardiolipin antibodies can affect the brain in ways that do not show up as an obvious clinical event like a stroke, which is a consideration that rarely makes it into the standard patient conversation about test results.